Table 1.
Randomized, double-blind, placebo-controlled trials included in the meta-analysis
| Incident haematological malignancies | |||||||
|---|---|---|---|---|---|---|---|
| Study | Agent | No. of subjects | Duration (years) | Statin group | Placebo group | RR (95% CI) | Reported outcome |
| 4S [24]* | Simvastatin | 4444 | Median: 10.4 | 17 of 2221 | 19 of 2223 | 0.90 (0.47, 1.72) | Incident haematological malignancies |
| ALERT [25] | Fluvastatin | 2094 | Mean: 5.1 | 11 of 1045 | 18 of 1049 | 0.61 (0.29, 1.29) | Incident haematological malignancies |
| HPS [26] | Simvastatin | 20536 | Mean: 5.0 | 64 of 10 269 | 52 of 10 267 | 1.23 (0.85, 1.77) | Incident haematological malignancies |
| LIPID [27] | Pravastatin | 9014 | Mean: 8.0 | 37 of 4512 | 52 of 4502 | 0.71 (0.47, 1.08) | Incident lymphomas and leukaemias |
| AFCAPS [28] | Lovastatin | 6605 | Mean: 5.2 | 12 of 3304 | 11 of 3301 | 1.09 (0.48, 2.47) | Incident lymphomas |
| CARE [29] | Pravastatin | 4159 | Mean: 4.8 | 8 of 2081 | 10 of 2078 | 0.80 (0.32, 2.02) | Incident lymphomas and leukaemias |
RR, Relative risk (risk ratio); CI, confidence interval.
*
Numbers in parentheses, reference citation.